4//SEC Filing
Exploration Capital Fund, LP 4
Accession 0001213900-23-093858
CIK 0000819050other
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 9:45 PM ET
Size
12.5 KB
Accession
0001213900-23-093858
Insider Transaction Report
Form 4
Exploration Capital Fund, LP
10% Owner
Transactions
- Purchase
Common Stock
2023-12-05$0.85/sh−5,188$4,410→ 682,767 total - Purchase
Common Stock
2023-12-04$0.85/sh−7,579$6,442→ 677,579 total - Purchase
Common Stock
2023-12-06$0.90/sh−17,233$15,510→ 700,000 total
Exploration Capital, LLC
10% Owner
Transactions
- Purchase
Common Stock
2023-12-05$0.85/sh−5,188$4,410→ 682,767 total - Purchase
Common Stock
2023-12-04$0.85/sh−7,579$6,442→ 677,579 total - Purchase
Common Stock
2023-12-06$0.90/sh−17,233$15,510→ 700,000 total
Transactions
- Purchase
Common Stock
2023-12-06$0.90/sh−17,233$15,510→ 700,000 total - Purchase
Common Stock
2023-12-05$0.85/sh−5,188$4,410→ 682,767 total - Purchase
Common Stock
2023-12-04$0.85/sh−7,579$6,442→ 677,579 total
Footnotes (2)
- [F1]Exploration Capital, LLC ("X-Cap") is the investment manager of Exploration Capital Fund, LP (the "Partnership") and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership. Exploration Capital General Partner, LLC (the "GP") is the general partner of the Partnership and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership.
- [F2]Stephen L. Gustin is the Managing Partner of X-Cap and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership. Mr. Gustin disclaims beneficial ownership of the reported securities held by the Partnership except to the extent of his pecuniary interest.
Documents
Issuer
Fresh Tracks Therapeutics, Inc.
CIK 0000819050
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001799866
Filing Metadata
- Form type
- 4
- Filed
- Dec 5, 7:00 PM ET
- Accepted
- Dec 6, 9:45 PM ET
- Size
- 12.5 KB